Proteomics International Laboratories (ASX:PIQ) said its PromarkerD predictive blood test has the potential to support earlier, more accurate identification of kidney disease risk in Aboriginal Australians with type 2 diabetes, according to a Monday filing with the Australian bourse.
The test delivered a 'rule out' rate of over 85% in Aboriginal participants, showing that a low score can reliably identify individuals unlikely to experience near-term kidney function decline.